Growth Metrics

Fulgent Genetics (FLGT) Asset Writedowns and Impairment (2016 - 2026)

Fulgent Genetics' Asset Writedowns and Impairment history spans 12 years, with the latest figure at $1.2 million for Q1 2026.

  • On a quarterly basis, Asset Writedowns and Impairment fell 42.7% to $1.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.0 million, a 4.84% decrease, with the full-year FY2025 number at $7.6 million, up 542.08% from a year prior.
  • Asset Writedowns and Impairment hit $1.2 million in Q1 2026 for Fulgent Genetics, down from $1.9 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for FLGT hit a ceiling of $11.6 million in Q1 2022 and a floor of -$2.5 million in Q1 2024.
  • Historically, Asset Writedowns and Impairment has averaged $3.7 million across 5 years, with a median of $2.1 million in 2025.
  • Biggest five-year swings in Asset Writedowns and Impairment: surged 987.78% in 2022 and later plummeted 2109.73% in 2024.
  • Tracing FLGT's Asset Writedowns and Impairment over 5 years: stood at $7.3 million in 2022, then plummeted by 52.7% to $3.5 million in 2023, then crashed by 57.11% to $1.5 million in 2024, then grew by 25.27% to $1.9 million in 2025, then plummeted by 35.87% to $1.2 million in 2026.
  • Business Quant data shows Asset Writedowns and Impairment for FLGT at $1.2 million in Q1 2026, $1.9 million in Q4 2025, and $9.9 million in Q2 2025.